News

NP2, the company’s first drug candidate in its nerve targeting drug delivery system (NTDDS) gene therapy platform, will be the subject of a pre-IND meeting with the FDA

The European Commission approved Rasilez alone or in combination with other high blood pressure therapies, based on data from more than 7,800 patients in 44 clinical studies which

Following a meeting with the FDA and subsequent statistical analyses, the company reported that despite the descriptive data showing numerical differences, the drug did not demonstrate a statistically

Based on the DMC’s recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation

The resubmission, based on a pivotal phase III trial, marks the beginning of a six-month review period by the FDA. In September 2006, the company received a complete

Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, reverse genetics can be a

All of the drug candidates under the deal were discontinued or de-prioritized in clinical trials for reasons other than safety, the company said. The agreement provides for payment

Eurand, which developed Amrix for ECR, will now work with Cephalon to support the commercialization of the product in the US. Eurand will receive royalty payments from Cephalon

The double-blind, placebo controlled study will be conducted at sites in the US, South Africa, Eastern Europe and India. The trial is designed to randomly assign approximately 1,200